Skip to main content

Table 2 Change from baseline in objective measures of affected ankle tenderness, joint function, and swelling

From: Randomized, double-blind, noninferiority study of diclofenac diethylamine 2.32% gel applied twice daily versus diclofenac diethylamine 1.16% gel applied four times daily in patients with acute ankle sprain

Least squares mean (SE)

DDEA 2.32% gel BID (N = 122)

DDEA 1.16% gel QID (N = 128)

Least squares mean difference (95% CI)a

Algometry, N/cm2

 Day 3

6.92 (0.85)

5.73 (0.83)

1.20 (−1.13, 3.54)

 Day 5

9.84 (0.97)

10.76 (0.94)

−0.93 (−3.60, 1.74)

 Day 8

17.06 (1.19)

15.60 (1.16)

1.46 (−1.83, 4.74)

Karlsson Scoring

 Day 3

16.26 (1.07)

15.52 (1.05)

0.74 (−2.23, 3.71)

 Day 5

27.94 (1.46)

28.22 (1.43)

−0.28 (−4.33, 3.77)

 Day 8

41.87 (1.59)

39.75 (1.56)

2.12 (−2.29, 6.54)

Figure of Eight Method

 Day 3

−0.42 (0.09)

−0.24 (0.09)

−0.18 (− 0.44, 0.07)

 Day 5

−0.97 (0.10)

−0.57 (0.10)

−0.39 (− 0.66, − 0.12)

 Day 8

−1.25 (0.10)

−0.87 (0.10)

−0.38 (− 0.66, − 0.10)

  1. BID twice daily, CI confidence interval, DDEA diclofenac diethylamine, QID four times daily, SE standard error
  2. aConfidence intervals encompass zero, indicating no significant difference between groups